Craneware sinks 25% as Peel Hunt cuts forecasts after cyber warning

Craneware shares plunged 25% to 1,006p after the healthcare software group reset its near-term outlook. The company now expects revenue of about US$185 million in the year ending June 2027, roughly flat with current annual recurring revenue, signaling stalled growth. Peel Hunt cut its profit forecasts and placed both its rating and target price under review.

Analysis

The key issue is not the single-year revenue reset but the implied collapse in incremental ARR conversion: if FY27 revenue merely matches the current recurring base, the market must now underwrite little to no net new growth for roughly two years. That changes CRW from a healthcare-software compounding story into a retention-and-execution story, likely forcing a lower revenue multiple until management demonstrates measurable reacceleration. A 25% one-day move may not fully reflect this if consensus earnings still embeds operating leverage from growth that no longer materializes.

Near term, estimate cuts should continue as analysts reassess bookings, implementation timing, customer expansion, and the cost base required to support the acquired platform. The most important next catalyst is evidence in the next two reporting updates that contracted backlog and sales pipeline are converting into recognized revenue; absent that, FY27 expectations could become another reset. Margin is the second-order risk: flat revenue against continued product, sales, and integration spending can produce disproportionate EBITDA and free-cash-flow downgrades.

The contrarian case is that the sell-off has discounted a temporary implementation bottleneck rather than impaired demand. That requires independently verifiable proof of stable gross retention, improving net revenue retention, and growth in signed but unrecognized contracted value—not management commentary on pipeline. Until those metrics emerge, lower-quality UK software peers with weak growth visibility can remain under pressure even if broad software valuation multiples stabilize.

A potential long is only appropriate after a hard-data inflection: two consecutive updates showing bookings/ARR above the newly implied run-rate and no further FY27 revision could drive a multiple recovery over 6-12 months. Conversely, a failure to protect recurring revenue would make the equity vulnerable to another leg down because the valuation floor is harder to establish when earnings visibility, rather than merely growth, is being repriced.

Key Decisions for Investors

• Avoid adding CRW into the initial decline; treat it as a 1-3 month estimate-revision short/watch candidate until revised consensus revenue, EBITDA, and free-cash-flow assumptions are published. A further material FY27 revenue or margin reset would validate downside; stable recurring-revenue retention and a quantified backlog conversion schedule would falsify the bearish view.
• For portfolios able to short UK small-cap liquidity, consider a small CRW short only after the post-results liquidity normalizes and with a tight stop on evidence of bookings acceleration or a strategic bid. Target risk/reward should be at least 2:1, as takeover optionality and an oversold technical bounce are meaningful risks after a one-day 25% decline.
• Do not use PEEL as a read-through trade: the broker’s economics are not materially exposed to a single client’s forecast revision. The relevant spillover is instead a higher required proof threshold for AIM-listed vertical-software names dependent on implementation-led revenue recognition.
• Set an alert for the next CRW trading update: require disclosure or credible evidence on gross retention, net retention, contracted backlog, implementation capacity, and FY27 revenue bridge before considering a long. If those data show the reset is timing-related rather than demand-related, initiate only a staged position over 6-18 months rather than attempting to catch the immediate rebound.